---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057443"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:11:53.885528+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25

## Summary
- RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.
- PROACT 1 protocol amendment submitted to FDA focusing on severe CKD (eGFR 20-35); enrollment to resume mid-2024.
- Appointed Ulrich Ernst as EVP Technical Operations and Lucio Tozzi as SVP Global Clinical Operations.
- Cash and equivalents $329M as of March 31, 2024, supporting operations into Q4 2025.
- Net loss before noncontrolling interest $35.3M for Q1 2024 vs $36.9M same period 2023.

## SEC filing metadata
- accession: 0000950170-24-057443
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/0000950170-24-057443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/prok-20240510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057443
- JSON: https://secwatch.observer/filing/0000950170-24-057443.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057443.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 10, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017024057443/0000950170-24-057443-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.